ROTS: reproducible RNA-seq biomarker detector-prognostic markers for clear cell renal cell cancer.
Seyednasrollah F, Rantanen K, Jaakkola P, Elo LL.
Nucleic Acids Res
44 :
2016
e1
31
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.
Genome Biol
17 :
2016
231
513
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
Huang Y, Wang J, Jia P, Li X, Pei G, Wang C, Fang X, Zhao Z, Cai Z, Yi X, Wu S, Zhang B.
Nat Commun
10 :
2019
1245
30
Classification of clear cell renal cell carcinoma based on PKM alternative splicing.
Li X, Turanli B, Juszczak K, Kim W, Arif M, Sato Y, Ogawa S, Turkez H, Nielsen J, Boren J, Uhlen M, Zhang C, Mardinoglu A.
Heliyon
6 :
2020
e03440
4
Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers.
Li X, Kim W, Arif M, Gao C, Hober A, Kotol D, Strandberg L, Forsström B, Sivertsson Å, Oksvold P, Turkez H, Grøtli M, Sato Y, Kume H, Ogawa S, Boren J, Nielsen J, Uhlen M, Zhang C, Mardinoglu A.
Cancers (Basel)
13 :
2021
348
8
Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning.
Li X, Kim W, Juszczak K, Arif M, Sato Y, Kume H, Ogawa S, Turkez H, Boren J, Nielsen J, Uhlen M, Zhang C, Mardinoglu A.
iScience
24 :
2021
102722
7
Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T, Sasaki T, Sato Y, Kume H, Ogawa S, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Sawada K, Imamura T, Mizuno R, Oya M.
Nat Commun
12 :
2021
5547
23
Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma.
Jiang A, Meng J, Bao Y, Wang A, Gong W, Gan X, Wang J, Bao Y, Wu Z, Lu J, Liu B, Wang L.
Front Oncol
11 :
2021
755212
14
Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome <i>via</i> Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity.
Jiang A, Meng J, Gong W, Zhang Z, Gan X, Wang J, Wu Z, Liu B, Qu L, Wang L.
Front Immunol
13 :
2022
842069
9
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
Li X, Shong K, Kim W, Yuan M, Yang H, Sato Y, Kume H, Ogawa S, Turkez H, Shoaie S, Boren J, Nielsen J, Uhlen M, Zhang C, Mardinoglu A.
EBioMedicine
78 :
2022
103963
7
A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H, Barberis A, Chervova O, Nassiri I, Voloshin V, Sato Y, Ogawa S, Fairfax B, Buffa F, Humphrey TC.
BMC Cancer
23 :
2023
721
1
